nodes	percent_of_prediction	percent_of_DWPC	metapath
Scopolamine—ABCB1—colon cancer	0.787	1	CbGaD
Scopolamine—CHRM3—ureter—colon cancer	0.0253	0.313	CbGeAlD
Scopolamine—CHRM3—muscle of abdomen—colon cancer	0.0182	0.225	CbGeAlD
Scopolamine—SI—embryo—colon cancer	0.0123	0.152	CbGeAlD
Scopolamine—Application site burn—Fluorouracil—colon cancer	0.00869	0.066	CcSEcCtD
Scopolamine—Temperature intolerance—Capecitabine—colon cancer	0.00775	0.0589	CcSEcCtD
Scopolamine—SI—digestive system—colon cancer	0.00766	0.0946	CbGeAlD
Scopolamine—Skin irritation—Fluorouracil—colon cancer	0.00421	0.032	CcSEcCtD
Scopolamine—Application site pain—Fluorouracil—colon cancer	0.00414	0.0314	CcSEcCtD
Scopolamine—CHRM5—epithelium—colon cancer	0.00389	0.048	CbGeAlD
Scopolamine—Abdominal cramps—Vincristine—colon cancer	0.00289	0.022	CcSEcCtD
Scopolamine—Abdominal cramps—Irinotecan—colon cancer	0.00282	0.0214	CcSEcCtD
Scopolamine—Speech disorder—Irinotecan—colon cancer	0.00221	0.0168	CcSEcCtD
Scopolamine—Speech disorder—Fluorouracil—colon cancer	0.00212	0.0161	CcSEcCtD
Scopolamine—CHRM3—smooth muscle tissue—colon cancer	0.00209	0.0259	CbGeAlD
Scopolamine—CHRM3—renal system—colon cancer	0.00202	0.0249	CbGeAlD
Scopolamine—ABCB1—blood vessel—colon cancer	0.00174	0.0215	CbGeAlD
Scopolamine—Photophobia—Fluorouracil—colon cancer	0.00171	0.013	CcSEcCtD
Scopolamine—CHRM3—digestive system—colon cancer	0.00165	0.0204	CbGeAlD
Scopolamine—Disorientation—Fluorouracil—colon cancer	0.00148	0.0112	CcSEcCtD
Scopolamine—Amnesia—Fluorouracil—colon cancer	0.00141	0.0107	CcSEcCtD
Scopolamine—Urinary retention—Vincristine—colon cancer	0.00135	0.0102	CcSEcCtD
Scopolamine—Irritability—Fluorouracil—colon cancer	0.00126	0.00958	CcSEcCtD
Scopolamine—Muscular weakness—Vincristine—colon cancer	0.00125	0.00949	CcSEcCtD
Scopolamine—Depressed level of consciousness—Capecitabine—colon cancer	0.00123	0.00933	CcSEcCtD
Scopolamine—Dry skin—Fluorouracil—colon cancer	0.00121	0.0092	CcSEcCtD
Scopolamine—Dry eye—Capecitabine—colon cancer	0.00118	0.00892	CcSEcCtD
Scopolamine—Muscular weakness—Fluorouracil—colon cancer	0.00117	0.00885	CcSEcCtD
Scopolamine—Dysuria—Vincristine—colon cancer	0.00115	0.0087	CcSEcCtD
Scopolamine—Dysphagia—Fluorouracil—colon cancer	0.00114	0.00867	CcSEcCtD
Scopolamine—Speech disorder—Methotrexate—colon cancer	0.0011	0.00836	CcSEcCtD
Scopolamine—Sweating—Vincristine—colon cancer	0.00105	0.00795	CcSEcCtD
Scopolamine—ABCB1—embryo—colon cancer	0.00104	0.0128	CbGeAlD
Scopolamine—Sweating—Irinotecan—colon cancer	0.00102	0.00774	CcSEcCtD
Scopolamine—Conjunctivitis—Fluorouracil—colon cancer	0.00099	0.00752	CcSEcCtD
Scopolamine—Amnesia—Capecitabine—colon cancer	0.000983	0.00746	CcSEcCtD
Scopolamine—Hallucination—Vincristine—colon cancer	0.000976	0.00741	CcSEcCtD
Scopolamine—Bradycardia—Irinotecan—colon cancer	0.000972	0.00738	CcSEcCtD
Scopolamine—Thirst—Capecitabine—colon cancer	0.000971	0.00737	CcSEcCtD
Scopolamine—Urinary tract disorder—Vincristine—colon cancer	0.000968	0.00735	CcSEcCtD
Scopolamine—Urethral disorder—Vincristine—colon cancer	0.000961	0.0073	CcSEcCtD
Scopolamine—Visual impairment—Irinotecan—colon cancer	0.00092	0.00699	CcSEcCtD
Scopolamine—Depressed level of consciousness—Methotrexate—colon cancer	0.000915	0.00694	CcSEcCtD
Scopolamine—Pharyngitis—Fluorouracil—colon cancer	0.000908	0.00689	CcSEcCtD
Scopolamine—Flushing—Irinotecan—colon cancer	0.000886	0.00673	CcSEcCtD
Scopolamine—Irritability—Capecitabine—colon cancer	0.000882	0.00669	CcSEcCtD
Scopolamine—Urinary retention—Capecitabine—colon cancer	0.000879	0.00667	CcSEcCtD
Scopolamine—Mental disorder—Vincristine—colon cancer	0.000859	0.00652	CcSEcCtD
Scopolamine—Arrhythmia—Irinotecan—colon cancer	0.000853	0.00648	CcSEcCtD
Scopolamine—Dry skin—Capecitabine—colon cancer	0.000847	0.00643	CcSEcCtD
Scopolamine—ABCB1—epithelium—colon cancer	0.000845	0.0104	CbGeAlD
Scopolamine—Arrhythmia—Fluorouracil—colon cancer	0.000817	0.0062	CcSEcCtD
Scopolamine—Muscular weakness—Capecitabine—colon cancer	0.000815	0.00619	CcSEcCtD
Scopolamine—Dysphagia—Capecitabine—colon cancer	0.000799	0.00606	CcSEcCtD
Scopolamine—Erythema—Fluorouracil—colon cancer	0.000796	0.00604	CcSEcCtD
Scopolamine—Agitation—Vincristine—colon cancer	0.000784	0.00595	CcSEcCtD
Scopolamine—ABCB1—renal system—colon cancer	0.000784	0.00969	CbGeAlD
Scopolamine—Vertigo—Vincristine—colon cancer	0.000767	0.00582	CcSEcCtD
Scopolamine—Vision blurred—Fluorouracil—colon cancer	0.00075	0.0057	CcSEcCtD
Scopolamine—Vertigo—Irinotecan—colon cancer	0.000747	0.00567	CcSEcCtD
Scopolamine—Dysuria—Capecitabine—colon cancer	0.000747	0.00567	CcSEcCtD
Scopolamine—Oedema—Vincristine—colon cancer	0.000697	0.00529	CcSEcCtD
Scopolamine—Conjunctivitis—Capecitabine—colon cancer	0.000692	0.00525	CcSEcCtD
Scopolamine—Confusional state—Irinotecan—colon cancer	0.000684	0.00519	CcSEcCtD
Scopolamine—Nervous system disorder—Vincristine—colon cancer	0.000683	0.00519	CcSEcCtD
Scopolamine—Oedema—Irinotecan—colon cancer	0.000678	0.00515	CcSEcCtD
Scopolamine—Hyperhidrosis—Vincristine—colon cancer	0.000674	0.00511	CcSEcCtD
Scopolamine—Nervous system disorder—Irinotecan—colon cancer	0.000665	0.00505	CcSEcCtD
Scopolamine—Irritability—Methotrexate—colon cancer	0.000656	0.00498	CcSEcCtD
Scopolamine—Hyperhidrosis—Irinotecan—colon cancer	0.000656	0.00498	CcSEcCtD
Scopolamine—Confusional state—Fluorouracil—colon cancer	0.000655	0.00497	CcSEcCtD
Scopolamine—Hypotension—Vincristine—colon cancer	0.000651	0.00494	CcSEcCtD
Scopolamine—ABCB1—lymphoid tissue—colon cancer	0.000651	0.00804	CbGeAlD
Scopolamine—Bradycardia—Capecitabine—colon cancer	0.000651	0.00494	CcSEcCtD
Scopolamine—Oedema—Fluorouracil—colon cancer	0.00065	0.00493	CcSEcCtD
Scopolamine—ABCB1—digestive system—colon cancer	0.000643	0.00794	CbGeAlD
Scopolamine—Nervous system disorder—Fluorouracil—colon cancer	0.000637	0.00484	CcSEcCtD
Scopolamine—Pharyngitis—Capecitabine—colon cancer	0.000634	0.00482	CcSEcCtD
Scopolamine—Tachycardia—Fluorouracil—colon cancer	0.000634	0.00481	CcSEcCtD
Scopolamine—Hypotension—Irinotecan—colon cancer	0.000634	0.00481	CcSEcCtD
Scopolamine—Urinary tract disorder—Capecitabine—colon cancer	0.000631	0.00479	CcSEcCtD
Scopolamine—Urethral disorder—Capecitabine—colon cancer	0.000627	0.00476	CcSEcCtD
Scopolamine—Visual impairment—Capecitabine—colon cancer	0.000616	0.00468	CcSEcCtD
Scopolamine—Hypotension—Fluorouracil—colon cancer	0.000607	0.00461	CcSEcCtD
Scopolamine—Somnolence—Irinotecan—colon cancer	0.000603	0.00458	CcSEcCtD
Scopolamine—Fatigue—Vincristine—colon cancer	0.000601	0.00456	CcSEcCtD
Scopolamine—Eye disorder—Capecitabine—colon cancer	0.000597	0.00453	CcSEcCtD
Scopolamine—Pain—Vincristine—colon cancer	0.000596	0.00452	CcSEcCtD
Scopolamine—Constipation—Vincristine—colon cancer	0.000596	0.00452	CcSEcCtD
Scopolamine—Flushing—Capecitabine—colon cancer	0.000593	0.0045	CcSEcCtD
Scopolamine—ABCB1—bone marrow—colon cancer	0.000593	0.00732	CbGeAlD
Scopolamine—Fatigue—Irinotecan—colon cancer	0.000585	0.00444	CcSEcCtD
Scopolamine—Pain—Irinotecan—colon cancer	0.00058	0.0044	CcSEcCtD
Scopolamine—Constipation—Irinotecan—colon cancer	0.00058	0.0044	CcSEcCtD
Scopolamine—Somnolence—Fluorouracil—colon cancer	0.000578	0.00439	CcSEcCtD
Scopolamine—Arrhythmia—Capecitabine—colon cancer	0.000571	0.00433	CcSEcCtD
Scopolamine—ABCB1—vagina—colon cancer	0.000568	0.00702	CbGeAlD
Scopolamine—Mental disorder—Capecitabine—colon cancer	0.00056	0.00425	CcSEcCtD
Scopolamine—Feeling abnormal—Irinotecan—colon cancer	0.000559	0.00424	CcSEcCtD
Scopolamine—Erythema—Capecitabine—colon cancer	0.000556	0.00422	CcSEcCtD
Scopolamine—Dysuria—Methotrexate—colon cancer	0.000556	0.00422	CcSEcCtD
Scopolamine—Pain—Fluorouracil—colon cancer	0.000556	0.00422	CcSEcCtD
Scopolamine—Abdominal pain—Vincristine—colon cancer	0.000551	0.00418	CcSEcCtD
Scopolamine—Body temperature increased—Vincristine—colon cancer	0.000551	0.00418	CcSEcCtD
Scopolamine—Body temperature increased—Irinotecan—colon cancer	0.000536	0.00407	CcSEcCtD
Scopolamine—Abdominal pain—Irinotecan—colon cancer	0.000536	0.00407	CcSEcCtD
Scopolamine—Feeling abnormal—Fluorouracil—colon cancer	0.000535	0.00406	CcSEcCtD
Scopolamine—Drowsiness—Methotrexate—colon cancer	0.00053	0.00402	CcSEcCtD
Scopolamine—Vision blurred—Capecitabine—colon cancer	0.000524	0.00398	CcSEcCtD
Scopolamine—Tremor—Capecitabine—colon cancer	0.000521	0.00396	CcSEcCtD
Scopolamine—Conjunctivitis—Methotrexate—colon cancer	0.000515	0.00391	CcSEcCtD
Scopolamine—Body temperature increased—Fluorouracil—colon cancer	0.000514	0.0039	CcSEcCtD
Scopolamine—Sweating—Methotrexate—colon cancer	0.000508	0.00386	CcSEcCtD
Scopolamine—Vertigo—Capecitabine—colon cancer	0.0005	0.00379	CcSEcCtD
Scopolamine—Asthenia—Vincristine—colon cancer	0.0005	0.00379	CcSEcCtD
Scopolamine—Asthenia—Irinotecan—colon cancer	0.000487	0.0037	CcSEcCtD
Scopolamine—ABCB1—liver—colon cancer	0.000479	0.00592	CbGeAlD
Scopolamine—Pharyngitis—Methotrexate—colon cancer	0.000472	0.00358	CcSEcCtD
Scopolamine—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—colon cancer	0.00047	0.00357	CcSEcCtD
Scopolamine—Urinary tract disorder—Methotrexate—colon cancer	0.00047	0.00357	CcSEcCtD
Scopolamine—Urethral disorder—Methotrexate—colon cancer	0.000466	0.00354	CcSEcCtD
Scopolamine—Dry mouth—Capecitabine—colon cancer	0.000463	0.00352	CcSEcCtD
Scopolamine—Dizziness—Vincristine—colon cancer	0.000461	0.0035	CcSEcCtD
Scopolamine—Pruritus—Fluorouracil—colon cancer	0.00046	0.00349	CcSEcCtD
Scopolamine—Visual impairment—Methotrexate—colon cancer	0.000459	0.00348	CcSEcCtD
Scopolamine—Confusional state—Capecitabine—colon cancer	0.000458	0.00348	CcSEcCtD
Scopolamine—Oedema—Capecitabine—colon cancer	0.000454	0.00345	CcSEcCtD
Scopolamine—Dizziness—Irinotecan—colon cancer	0.000449	0.00341	CcSEcCtD
Scopolamine—Nervous system disorder—Capecitabine—colon cancer	0.000445	0.00338	CcSEcCtD
Scopolamine—Eye disorder—Methotrexate—colon cancer	0.000445	0.00338	CcSEcCtD
Scopolamine—Tachycardia—Capecitabine—colon cancer	0.000443	0.00336	CcSEcCtD
Scopolamine—Vomiting—Vincristine—colon cancer	0.000443	0.00336	CcSEcCtD
Scopolamine—Skin disorder—Capecitabine—colon cancer	0.000441	0.00335	CcSEcCtD
Scopolamine—Rash—Vincristine—colon cancer	0.000439	0.00333	CcSEcCtD
Scopolamine—Hyperhidrosis—Capecitabine—colon cancer	0.000439	0.00333	CcSEcCtD
Scopolamine—Dermatitis—Vincristine—colon cancer	0.000439	0.00333	CcSEcCtD
Scopolamine—Headache—Vincristine—colon cancer	0.000436	0.00331	CcSEcCtD
Scopolamine—Vomiting—Irinotecan—colon cancer	0.000431	0.00327	CcSEcCtD
Scopolamine—Dizziness—Fluorouracil—colon cancer	0.00043	0.00326	CcSEcCtD
Scopolamine—Rash—Irinotecan—colon cancer	0.000428	0.00325	CcSEcCtD
Scopolamine—Dermatitis—Irinotecan—colon cancer	0.000427	0.00324	CcSEcCtD
Scopolamine—Headache—Irinotecan—colon cancer	0.000425	0.00323	CcSEcCtD
Scopolamine—Hypotension—Capecitabine—colon cancer	0.000424	0.00322	CcSEcCtD
Scopolamine—Mental disorder—Methotrexate—colon cancer	0.000417	0.00316	CcSEcCtD
Scopolamine—Erythema—Methotrexate—colon cancer	0.000414	0.00314	CcSEcCtD
Scopolamine—Nausea—Vincristine—colon cancer	0.000414	0.00314	CcSEcCtD
Scopolamine—Vomiting—Fluorouracil—colon cancer	0.000413	0.00314	CcSEcCtD
Scopolamine—Rash—Fluorouracil—colon cancer	0.00041	0.00311	CcSEcCtD
Scopolamine—Dermatitis—Fluorouracil—colon cancer	0.000409	0.00311	CcSEcCtD
Scopolamine—Headache—Fluorouracil—colon cancer	0.000407	0.00309	CcSEcCtD
Scopolamine—Nausea—Irinotecan—colon cancer	0.000403	0.00306	CcSEcCtD
Scopolamine—Fatigue—Capecitabine—colon cancer	0.000392	0.00297	CcSEcCtD
Scopolamine—Vision blurred—Methotrexate—colon cancer	0.00039	0.00296	CcSEcCtD
Scopolamine—Pain—Capecitabine—colon cancer	0.000388	0.00295	CcSEcCtD
Scopolamine—Constipation—Capecitabine—colon cancer	0.000388	0.00295	CcSEcCtD
Scopolamine—Nausea—Fluorouracil—colon cancer	0.000386	0.00293	CcSEcCtD
Scopolamine—Feeling abnormal—Capecitabine—colon cancer	0.000374	0.00284	CcSEcCtD
Scopolamine—Vertigo—Methotrexate—colon cancer	0.000372	0.00282	CcSEcCtD
Scopolamine—ABCB1—lymph node—colon cancer	0.000367	0.00454	CbGeAlD
Scopolamine—Body temperature increased—Capecitabine—colon cancer	0.000359	0.00272	CcSEcCtD
Scopolamine—Abdominal pain—Capecitabine—colon cancer	0.000359	0.00272	CcSEcCtD
Scopolamine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—colon cancer	0.00035	0.00266	CcSEcCtD
Scopolamine—Confusional state—Methotrexate—colon cancer	0.000341	0.00259	CcSEcCtD
Scopolamine—Nervous system disorder—Methotrexate—colon cancer	0.000332	0.00252	CcSEcCtD
Scopolamine—Skin disorder—Methotrexate—colon cancer	0.000328	0.00249	CcSEcCtD
Scopolamine—Hyperhidrosis—Methotrexate—colon cancer	0.000327	0.00248	CcSEcCtD
Scopolamine—Asthenia—Capecitabine—colon cancer	0.000326	0.00247	CcSEcCtD
Scopolamine—Pruritus—Capecitabine—colon cancer	0.000321	0.00244	CcSEcCtD
Scopolamine—Hypotension—Methotrexate—colon cancer	0.000316	0.0024	CcSEcCtD
Scopolamine—Somnolence—Methotrexate—colon cancer	0.000301	0.00228	CcSEcCtD
Scopolamine—Dizziness—Capecitabine—colon cancer	0.0003	0.00228	CcSEcCtD
Scopolamine—Fatigue—Methotrexate—colon cancer	0.000291	0.00221	CcSEcCtD
Scopolamine—Pain—Methotrexate—colon cancer	0.000289	0.00219	CcSEcCtD
Scopolamine—Vomiting—Capecitabine—colon cancer	0.000289	0.00219	CcSEcCtD
Scopolamine—Rash—Capecitabine—colon cancer	0.000286	0.00217	CcSEcCtD
Scopolamine—Dermatitis—Capecitabine—colon cancer	0.000286	0.00217	CcSEcCtD
Scopolamine—Headache—Capecitabine—colon cancer	0.000284	0.00216	CcSEcCtD
Scopolamine—Feeling abnormal—Methotrexate—colon cancer	0.000279	0.00211	CcSEcCtD
Scopolamine—Nausea—Capecitabine—colon cancer	0.00027	0.00205	CcSEcCtD
Scopolamine—Abdominal pain—Methotrexate—colon cancer	0.000267	0.00203	CcSEcCtD
Scopolamine—Body temperature increased—Methotrexate—colon cancer	0.000267	0.00203	CcSEcCtD
Scopolamine—Asthenia—Methotrexate—colon cancer	0.000243	0.00184	CcSEcCtD
Scopolamine—Pruritus—Methotrexate—colon cancer	0.000239	0.00182	CcSEcCtD
Scopolamine—Dizziness—Methotrexate—colon cancer	0.000224	0.0017	CcSEcCtD
Scopolamine—Vomiting—Methotrexate—colon cancer	0.000215	0.00163	CcSEcCtD
Scopolamine—Rash—Methotrexate—colon cancer	0.000213	0.00162	CcSEcCtD
Scopolamine—Dermatitis—Methotrexate—colon cancer	0.000213	0.00162	CcSEcCtD
Scopolamine—Headache—Methotrexate—colon cancer	0.000212	0.00161	CcSEcCtD
Scopolamine—Nausea—Methotrexate—colon cancer	0.000201	0.00152	CcSEcCtD
